<DOC>
	<DOCNO>NCT00238433</DOCNO>
	<brief_summary>RATIONALE : Chemotherapy , busulfan , melphalan , thiotepa , may destroy cancerous blood-forming cell ( stem cell ) blood bone marrow . Giving patient healthy stem cell help bone marrow make new stem cell become red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well busulfan , melphalan , thiotepa work treat patient undergo autologous stem cell transplant Hodgkin 's non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Busulfan , Melphalan , Thiotepa Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Hodgkin 's Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic efficacy myeloablative preparative regimen comprise busulfan , melphalan , thiotepa follow autologous peripheral blood stem cell ( PBSC ) transplantation patient Hodgkin 's non-Hodgkin 's lymphoma . - Determine toxic effect preparative regimen patient . OUTLINE : - Myeloablative preparative regimen : Patients receive busulfan IV 3 hour day -8 -6 , melphalan IV 15-30 minute day -5 -4 , thiotepa IV 2 hour day -3 -2 . - Peripheral blood stem cell ( PBSC ) transplantation : Patients undergo PBSC transplantation day 0 follow filgrastim ( G-CSF ) IV 30 minute begin day 5 continue blood count recover . - Intrathecal chemotherapy : Patients history treat CNS disease high-risk CNS relapse receive methotrexate cytarabine intrathecally ( IT ) 2 dos within 10 day prior transplantation 4-6 dos begin day 32 post-transplantation . - Consolidation therapy : Patients residual bulk disease 80-100 day post-transplantation &gt; 2.5 cm CT scan may undergo local radiotherapy residual scar/disease provide encompassed single radiation port volume lung irradiate ≤ 20 % . After completion study treatment , patient follow weekly 1 month , monthly 6 month , every 3 month 6 month , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Intermediate highgrade nonHodgkin 's lymphoma ( NHL ) , meet 1 follow criterion : In first complete remission ( CR ) AND highrisk relapse , define follow criterion : High ageadjusted International Prognostic Index category AND meet follow criterion diagnosis : Stage III IV disease Lactic dehydrogenase abnormal ECOG 02 Mantle cell histology Primary refractory disease Beyond first CR Lowgrade NHL Beyond second relapse Hodgkin 's lymphoma Primary refractory disease OR beyond first CR Must adequate number store autologous peripheral blood stem cell ( PBSCs ) ( i.e. , 2.0 x 10^6 CD34positive cells/kg ) Patients able mobilize sufficient number PBSCs may use bone marrow instead No active CNS disease NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 0 70 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) AST ALT &lt; 3 time ULN Renal Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 50 mL/min Pulmonary No significant pulmonary dysfunction , define DLCO &lt; 60 % predict Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 2 month study participation HIV negative No significant active infection would preclude PBSC transplantation PRIOR CONCURRENT THERAPY : Biologic therapy No prior transplantation No concurrent blood product PBSC transplantation Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy More 60 day since prior local regional radiotherapy Surgery Not specify Other More 30 day since prior investigational drug No concurrent amphotericin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage III childhood anaplastic large cell lymphoma</keyword>
	<keyword>stage IV childhood anaplastic large cell lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>